Smith & Nephew and Johnson & Johnson orthopaedics merger talks collapse over CEO dispute
Negotiations between Smith & Nephew and Johnson & Johnson’s orthopaedics division fell apart after the parties could not agree on who would lead the combined business. Both sides had aligned on the financial terms, but Smith & Nephew insisted that its current chief executive, Deepak S. Nath, remain CEO, a condition J&J would not accept. The proposed transaction would have valued J&J’s hip and knee replacement unit at up to $22 billion, with J&J shareholders slated to own about 50.1% of the new entity.
Why it matters
The collapse removes a potential large‑scale consolidation in the orthopaedics market, keeping the two companies separate and preserving existing competitive dynamics. Investors in both stocks may see short‑term price pressure as the deal’s premium valuation disappears.
Key facts
- 1The merger talks collapsed on 23 Oct 2026 after a disagreement over the CEO of the combined company. investing.com
- 2Smith & Nephew required its current chief executive Deepak S. Nath to stay on as CEO of the merged entity. investing.com
- 3The deal would have valued Johnson & Johnson’s orthopaedics unit at up to $22 billion. investing.com
- 4Johnson & Johnson shareholders would have owned about 50.1% of the new company. investing.com
- 5Smith & Nephew’s market capitalisation was £9.4 billion (approximately $12.58 billion). investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.